key: cord-0761188-kaccgoza authors: Bhutani, Mohit; Hernandez, Paul; Bourbeau, Jean; Dechman, Gail; Penz, Erika; Aceron, Raymond; Beauchamp, Marla; Wald, Joshua; Stickland, Michael; Olsen, Sharla-Rae; Goodridge, Donna title: KEY HIGHLIGHTS of the Canadian Thoracic Society’s Position Statement on the Optimization of Chronic Obstructive Pulmonary Disease Management during the COVID-19 Pandemic date: 2020-05-16 journal: Chest DOI: 10.1016/j.chest.2020.05.530 sha: 8caee8b26bd0eda8cff8b4d449c97a7b181db2e3 doc_id: 761188 cord_uid: kaccgoza nan Patients living with Chronic Obstructive Pulmonary Disease (COPD) represent a vulnerable population during the COVID-19 pandemic. Clinicians and patients have many questions regarding the acute and chronic management of COPD during the pandemic. This commentary summarizes the Canadian Thoracic Society's (CTS) position statement on managing COPD during the COVID-19 pandemic 1 in an easy FAQ format. The full COPD position statement, as well as other valuable clinical tools including links to online patient support programs for self-management and exercise/pulmonary rehabilitation, can be found at https://cts-sct.ca/covid-19/. Patients with COPD should stay at home as much as possible, including working from home, if feasible. If you must leave the home, we suggest that all patients follow current local, national and global public health advisories with respect to the indications for physical distancing and isolation. Patients should wash their hands with soap and water frequently for 20 seconds or use alcohol-based hand sanitizer containing at least 60% alcohol. Consider having at least a 30-day supply of all medications on hand to reduce the need for leaving the home, or select delivery options at your pharmacy, or have trusted individuals pick up your medication. Longitudinal experience with seasonal influenza and preliminary data in SARS-CoV-2 infection (see below) suggests that patients with chronic lung disease are at risk for severe complications of SARS-CoV-2 infection (COVID-19). Physical distancing is an important public health measure to 'flatten the curve' of community spread of the virus. The workplace is a social environment which may expose patients to others in their community, particularly if physical distancing in the workplace setting is difficult to implement. Until we fully understand the risks associated with SARS-CoV-2 infection in patients with chronic lung disease we have placed a high value on limiting exposure based on prior experience with influenza. Are COPD patients at higher risk of acquiring the SARS-CoV-2 infection? Viral respiratory tract infections are a common cause of COPD exacerbations. 2 However, according to current available data, COPD patients are NOT at an increased risk of acquiring SARS-CoV-2 infection. Published literature on the clinical characteristics of patients admitted to hospital for a SARS-CoV-2 infection suggest that COPD patients are not overrepresented when compared to the general population. 3, 4, 5, 6 Will COPD patients have more severe symptoms or disease course due to COVID-19? COPD patients hospitalized due to COVID-19 are more likely to require intensive care unit (ICU) support and have higher mortality when compared to other patient groups. 7 We recommend that usual maintenance and exacerbation management for COPD be continued according to current CTS treatment guidelines. 10 Based on what we know about viral respiratory infections in patients with COPD, optimal pharmacological treatment is the best way to prevent exacerbations and/or reduce the severity of exacerbations. Maintenance inhaled therapies have been shown to improve lung function, symptoms, quality of life and decrease the risk of future exacerbations, including those precipitated by viral infections. There is no evidence that inhaled corticosteroids (ICS) increase the risk of acquiring SARS-CoV-2 infection or complicate/worsen this infection, such as increasing the need for hospitalization, intubation for mechanical ventilation, or death. This includes patients using their ICS in combination inhalers with long-acting bronchodilators (i.e. long-acting muscarinic antagonist (LAMA) and/or long-acting beta-2agonist (LABA)), such as ICS/LABA or ICS/LABA/LAMA combination inhalers. Patients should continue their maintenance and exacerbation management for COPD according to CTS treatment guidelines. 10, 11 This question needs careful consideration, as we need to separate the use of systemic corticosteroids for treatment of AECOPD from the use of systemic corticosteroids in a more general setting of COVID-19. In the absence of evidence of harm and an expectation of a low risk of harm, we prioritized the high value of current evidence-based recommendations to treat AECOPD with prednisone to reduce the need for urgent health service utilization. The high value to reduce acute care utilization supersedes the low risk of concern that prednisone may prolong viral replication 1 . It remains unclear as to whether prednisone is helpful or harmful in the treatment of COVID-19. Most of what we know comes from studies on SARS-CoV-2 acute lung injury. Russel and colleagues reviewed observational data and concluded there was no benefit to using prednisone to treat SARS-CoV-2 related acute lung injury. 12 However, this literature is evolving and the evidence of the benefit/risk of systemic steroids may change. We do not recommend the use of a nebulizer during the pandemic as there is an increased risk of aerosol spread of virus particles 13 . Instead, patients should use metered dose inhalers with spacing devices, soft mist inhalers or dry powder inhalers to administer all COPD medications at home, and inside healthcare facilities and nursing homes. Patients who are already using nebulizers at home should continue to do so until they can be switched to alternative delivery methods. However, they should consider nebulizing their medicines in a separate room from others in the house, and implement other infection control recommendations. In-person programs are closed until further notice; however, self-management and pulmonary rehabilitation counseling can still be done by telephone or tele-health technologies in some institutions. Patients should remain physically active (e.g. daily walks while physical distancing, and doing functional resistance exercises for strength training) and continue their treatment plan (regular medications and self-management using their action plan with additional treatment in the event of an exacerbation). The CTS COVID-19 webpage (https://cts-sct.ca/covid-19/) provides links to online resources that can help facilitate the teaching and implementation of self-management and rehabilitation strategies. Yes. Patients who currently are on home oxygen should continue to use it as prescribed. They should follow the manufacturer's instructions for cleaning and maintenance of their equipment. If the patient has had to increase the flow rate, they should inform the physician, and/or case manager. If in extreme distress, they should call emergency medical services. The COVID-19 pandemic is a rapidly evolving situation. Health care professionals are advised to monitor the Canadian Thoracic Society website for additional COPD resources (action plans and tutorial videos for adults for the proper use of inhalers, etc.). Updates on COVID-19 and other lung diseases (such as Asthma) and a link to recommendations regarding the clinical management of patient's in the event of a Salbutamol MDI shortage can also be found on this webpage. Addressing therapeutic questions to help Canadian health care professionals optimize COPD management for their patients during the COVID-19 pandemic COPD exacerbations: defining their cause and prevention Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan Clinical Characteristics of Coronavirus Disease 2019 in China COVID-19) Outbreak in the Republic of Korea from Clinical Characteristics of Covid-19 in New York City Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis The impact of COPD and smoking history on the severity of Covid-19: A systemic review and meta-analysis Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respiratory Medicine. 2020 Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD -2019 update of evidence Canadian Thoracic Society recommendations for management of COPD -2008 update -highlights for primary care Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1